Previous Next Low-value Care Cleveland Clinic and Mount Sinai Won’t Administer Aduhelm to Patients Abstract: The rejection of the new Alzheimer’s drug by the two major medical centers is one of the starkest signs of concern over its approval by the F.D.A. Publication: The New York Times Date Published: July 14, 2021 Author(s): Pam Belluck View This Resource